{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+Samples+for+Biomarkers&page=3", "query": { "intervention": "Blood Samples for Biomarkers", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1291, "total_pages": 130, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+Samples+for+Biomarkers&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+Samples+for+Biomarkers&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T15:23:55.899Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03472586", "title": "Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in the Liver", "Metastatic Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Embolization Therapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-05-02", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03472586" }, { "nct_id": "NCT03629717", "title": "RANKL Inhibition and Breast Tissue Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer Prevention", "Mammographic Density" ], "interventions": [ { "name": "Ultrasound-guided core needle biopsy", "type": "PROCEDURE" }, { "name": "Denosumab", "type": "DRUG" }, { "name": "Blood draw", "type": "PROCEDURE" }, { "name": "Calcium", "type": "DRUG" }, { "name": "Vitamin D", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "FEMALE", "summary": "35 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2018-06-01", "completion_date": "2018-12-03", "has_results": false, "last_update_posted_date": "2024-10-16", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03629717" }, { "nct_id": "NCT00109018", "title": "Biomarkers for Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronary Artery Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 120, "start_date": "2005-04-19", "completion_date": "2009-04-15", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109018" }, { "nct_id": "NCT03064360", "title": "Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ischemic Heart Disease" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Patient Activity", "type": "DEVICE" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "DEVICE", "BEHAVIORAL" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "105 Years", "sex": "ALL", "summary": "18 Years to 105 Years" }, "enrollment_count": 200, "start_date": "2017-02-13", "completion_date": "2020-01-01", "has_results": false, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064360" }, { "nct_id": "NCT05019625", "title": "Biomarker Development for Muscular Dystrophies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy", "Duchenne Muscular Dystrophy", "Becker Muscular Dystrophy", "Facioscapulohumeral Muscular Dystrophy" ], "interventions": [], "intervention_types": [], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 465, "start_date": "2015-02-20", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Winston-Salem, North Carolina • Pittsburgh, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05019625" }, { "nct_id": "NCT02909504", "title": "Gao NARASD Lithium Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Lithium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Keming Gao", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2016-09", "completion_date": "2018-11", "has_results": true, "last_update_posted_date": "2020-07-10", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02909504" }, { "nct_id": "NCT03452332", "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cervical Adenocarcinoma", "Advanced Vaginal Carcinoma", "Advanced Vulvar Carcinoma", "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma", "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma", "Metastatic Cervical Adenocarcinoma", "Metastatic Cervical Carcinoma", "Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Metastatic Vaginal Adenocarcinoma", "Metastatic Vaginal Carcinoma", "Metastatic Vulvar Carcinoma", "Recurrent Cervical Adenocarcinoma", "Recurrent Cervical Carcinoma", "Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Vaginal Cancer AJCC v8", "Stage III Vulvar Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Vulvar Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Vulvar Cancer AJCC v8", "Stage IIIC Vulvar Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Adenocarcinoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2018-07-18", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452332" }, { "nct_id": "NCT06320717", "title": "AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Blood sample", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-01-02", "completion_date": "2026-12-02", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 2, "location_summary": "Buffalo, New York • West Islip, New York", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "West Islip", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06320717" }, { "nct_id": "NCT03600155", "title": "Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Allogeneic Hematopoietic Stem Cell Transplantation Recipient", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2018-10-11", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600155" }, { "nct_id": "NCT05837455", "title": "NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cancer of the Breast" ], "interventions": [ { "name": "VENTANA MIB-1 Ki67 assay", "type": "DEVICE" }, { "name": "Oncotype DX® Recurrence Score", "type": "DEVICE" }, { "name": "PAM50-based Prosigna breast cancer gene signature assay", "type": "DEVICE" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Combination anthracycline and/or taxane based treatment", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 81, "start_date": "2024-05-30", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-02T15:23:55.899Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05837455" } ] }